Clinical study

This study suggests that cumulative infliximab exposure over time (AUC) — not just trough levels — may predict infection risk in people with IBD. That could affect how clinicians use therapeutic drug monitoring to...

A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...

The paper provides genetic evidence that acute pancreatitis and Crohn’s disease share polygenic risk and converge on immune and inflammatory pathways; this may explain some observed comorbidity and points to biological...

Non-invasive blood biomarkers that predict who will respond to therapy could help personalize treatment and avoid ineffective medications. This study identifies plasma miR-145 and miR-191 as potential predictors of...

If validated, a genetic marker (IL12B rs6887695) might help predict which patients are more likely to benefit from ustekinumab, potentially informing personalized treatment choices in IBD.

Children with newly diagnosed ulcerative colitis in this study commonly had reduced muscle mass (sarcopenia) at diagnosis, and the degree of muscle loss correlated with higher disease activity and inflammation....

The study describes a new berberine-containing nanocomplex that reduced inflammation and improved gut barrier function in cell, mouse, and organoid models of ulcerative colitis, suggesting a potential new direction for...

Patient-centered measures help clinics track and improve care experiences important to people with IBD. A validated patient-developed PREM could better reflect patient priorities and support quality improvement in UK IBD...

Wearable-derived digital biomarkers aim to detect flares earlier and reduce reliance on questionnaires; patients' acceptance is essential for real-world use. High reported willingness suggests patient-centered...

Knowing a patient’s estimated infliximab clearance before starting rescue therapy for acute severe ulcerative colitis could help identify who may need higher or intensified induction dosing and who might be at greater...

The study suggests there may be stage-specific differences in mucosal IgA and IgG plasma cell patterns in UC, which could help researchers understand mucosal immunity changes across active disease, quiescence, and...

Many people with IBD remain symptomatic even when tests show little or no inflammation; recognising these persistent symptoms as a separate treatment target could improve quality of life. This reframes care to address...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Computer Methods in...

Patients and clinicians want to know whether tofacitinib raises blood clotting or platelet activation risk in ulcerative colitis, because similar safety concerns were reported in other diseases.

ITB can closely mimic Crohn’s disease, so this study is relevant because it describes diagnostic test yields and illustrates that targeted TB testing and therapeutic trials of antituberculosis treatment can help...

Researchers and clinicians interested in cross-disease host–microbe interactions may find that an IBD–CRC shared microbial/host signature could have prognostic importance beyond the gut, here in bladder cancer.

The study identifies blood gene-expression patterns linked to response to TNF-alpha inhibitors and highlights overlap between psoriasis and IBD, which could point to shared biomarkers or mechanisms relevant to treatment...

The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.

Fatigue affects more than half of people with IBD and is a leading cause of impaired quality of life. A machine-learning approach that identifies distinct patient-level patterns may help researchers and clinicians...

The study suggests a probiotic–ω‑3 combination (a synbiotic) might boost the anti‑inflammatory, pro‑resolving effects of ω‑3s in colonic tissue—potentially relevant for people with ulcerative colitis looking for adjunct...

Real-world 52-week data suggest mirikizumab can produce meaningful remission and reasonable drug persistence in patients with treatment-experienced ulcerative colitis. This is especially relevant for people who have not...

Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...

The study links a specific gut microbe and its metabolite to reduced inflammation and improved barrier function in ulcerative colitis models and cohort comparisons, suggesting a potential new microbiome-targeted therapy...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemia medica.

Patients who present with new radiologic terminal ileitis sometimes develop Crohn’s disease. Identifying simple blood and imaging markers that predict who is at higher risk could help prioritize follow-up or specialist...

This study suggests that a confirmed Campylobacter stool infection in people with IBD was followed by higher rates of flare and need for treatment escalation within 12 months, so infected patients might need closer...

A validated Spanish IBD-Disk gives Spanish-speaking patients and clinicians a brief, validated tool to measure disability and global health in IBD, supporting consistent monitoring and research across Spanish-speaking...

Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...

Thalidomide can help treat refractory pediatric IBD but causes peripheral neuropathy. Knowing a cumulative-dose threshold linked to neuropathy could help clinicians balance benefit and neurotoxicity risk.

The study describes a targeted oral delivery system for 5-ASA that aims to concentrate drug release in the colon and also leverage inulin’s prebiotic/immunomodulatory properties—potentially improving effectiveness and...

The study connects a bothersome UC symptom (bowel urgency) to intestinal ultrasound signs of transmural inflammation, suggesting ultrasound might help explain and track symptom-related inflammation without relying solely...

SRCEUS may offer higher-resolution, noninvasive assessment of intestinal microvascular changes that correspond to Crohn disease activity, which could improve monitoring and reduce reliance on invasive tests.

Identifies a stromal-cell subset marked by TIMP1 that may play a role in UC pathogenesis and might serve as a candidate biomarker or therapeutic target; useful for researchers and clinicians following emerging...

This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...

The paper presents a proof-of-concept immune-based assay to match donors and recipients for FMT in IBD, which could help explain variable FMT outcomes and improve donor selection if validated.

The study suggests a hidden, early molecular defect that leaves intestinal cells primed to die even during clinical remission, which could help explain why flares recur. Measuring these molecular signals might eventually...

Intestinal barrier dysfunction is a likely driver of inflammation and flares in ulcerative colitis, so therapies that restore barrier integrity could help reduce disease activity and recurrence. This review highlights...

The study suggests shared MHC/HLA genetic variants link ulcerative colitis and gastric cancer risk in East Asians, highlighting potential common immune-related susceptibility that could inform research on disease...

Older adults with IBD are under-represented in trials, so age-specific benefits and harms of newer oral drugs (JAK inhibitors and S1P modulators) are uncertain. Clinicians and patients may need to weigh efficacy against...

If pre‑treatment biopsy features predict response to ustekinumab, clinicians might better select which UC patients are likely to benefit, potentially avoiding ineffective therapy for some and speeding effective treatment...

The study provides real-world data on ozanimod effectiveness, safety, and how prior biologic exposure (notably vedolizumab) may affect treatment persistence—information relevant for treatment planning in UC.

New colon-targeted formulations aim to concentrate treatment where inflammation is in ulcerative colitis, which could increase benefit and reduce systemic side effects. Formulation research like this is an early step...

The work links climate and sociodemographic context to IBD burden in tropical regions, which can influence diagnostic recognition, resource needs, and research priorities for communities where IBD is rising.

Automated, quantitative analysis of pathology slides could reduce variability in histological scoring and help track histological healing — a growing therapeutic target in ulcerative colitis.

This project tests whether common nanoplastics that people ingest could damage the gut barrier, alter gut microbes’ estrogen metabolism, and injure enteric nerves — processes that might increase risk or severity of IBD.

This study links genetic variation in fatty-acid–desaturase genes with membrane PUFA profiles and inflammatory markers in Crohn’s disease. If replicated, erythrocyte desaturase indices could become integrative biomarkers...

Antibiotic use patterns in hospitalized IBD patients affect infection risks, microbiome impact, resistance pressure, length of stay, and costs. Shifting focus from simple exposure counts to intensity and escalation can...

Researchers are studying a parasite-derived protein (Fh15) that may reduce neutrophil-driven inflammation in sepsis and ulcerative colitis models; this could point toward new anti-inflammatory drug approaches in the...